Core Viewpoint - Kezar Life Sciences, Inc. (KZR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Stock Performance - The Zacks rating system focuses on a company's changing earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5][7]. - For Kezar Life Sciences, the Zacks Consensus Estimate for the fiscal year ending December 2025 is projected at -$8.19 per share, reflecting a 27.5% change from the previous year [9]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Kezar Life Sciences to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].

908 Devices Inc. (MASS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ear ...

Core Viewpoint - Fathom Holdings (FTHM) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, indicating that revisions in earnings estimates can lead to significant price changes [4][6]. - For Fathom Holdings, the rising earnings estimates suggest an improvement in the company's underlying business, which is expected to positively influence its stock price [5]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks receive a 'Strong Buy' or 'Buy' rating, indicating superior earnings estimate revisions [9][10]. Earnings Estimate Revisions for Fathom Holdings - For the fiscal year ending December 2025, Fathom Holdings is projected to earn -$0.33 per share, reflecting a 69.2% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Fathom Holdings has increased by 7.8%, indicating a positive trend in earnings expectations [8].

Core Viewpoint - Nerdy Inc. (NRDY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Recent Performance and Projections - For the fiscal year ending December 2025, Nerdy is expected to earn -$0.33 per share, reflecting a 13.2% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Nerdy has increased by 20.8%, indicating a positive trend in earnings expectations [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - The upgrade of Nerdy to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Legacy Education Inc. (LGCY) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Legacy Education Inc. projects earnings of $0.59 per share for the fiscal year ending June 2025, reflecting an 11.3% year-over-year increase [9]. - Over the past three months, the Zacks Consensus Estimate for the company has risen by 2.6%, indicating a trend of increasing earnings estimates [9]. Zacks Rating System - The Zacks rating system evaluates stocks based on earnings estimate revisions, categorizing them into five groups from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [8]. - The system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, highlighting the effectiveness of earnings estimate revisions in predicting stock performance [8]. Market Implications - The upgrade to Zacks Rank 2 positions Legacy Education Inc. in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term due to favorable earnings estimate revisions [11]. - Rising earnings estimates are correlated with stock price movements, as institutional investors often adjust their valuations based on these estimates, leading to buying or selling actions that affect stock prices [5][6].

Core Viewpoint - Backblaze, Inc. (BLZE) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in stock price movements [4]. Company Performance Indicators - For the fiscal year ending December 2025, Backblaze is expected to earn -$0.13 per share, reflecting a 67.5% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Backblaze has increased by 9%, indicating a positive trend in earnings outlook [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Backblaze's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Gogo (GOGO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying or selling, which affects stock prices [4]. Gogo's Earnings Outlook - Gogo is projected to earn $0.44 per share for the fiscal year ending December 2025, reflecting a year-over-year decline of 2.2% [8]. - Over the past three months, the Zacks Consensus Estimate for Gogo has increased by 5.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Gogo's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Insights - Epsilon Energy Ltd. (EPSN) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook for its earnings estimates, which is a significant factor influencing stock prices [1][4][11] Earnings Estimates and Revisions - The Zacks Consensus Estimate for Epsilon Energy indicates expected earnings of $0.48 per share for the fiscal year ending December 2025, reflecting a substantial year-over-year increase of 200% [9] - Over the past three months, the Zacks Consensus Estimate for Epsilon Energy has risen by 29.7%, showcasing a trend of increasing earnings estimates [9] Zacks Rating System - The Zacks rating system is based solely on a company's earnings picture, tracking changes in earnings estimates from sell-side analysts [2][3] - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988, indicating a strong performance potential [8] Market Implications - The upgrade to Zacks Rank 1 positions Epsilon Energy in the top 5% of Zacks-covered stocks, suggesting a likelihood of upward price movement in the near term due to improved earnings outlook [11] - Rising earnings estimates are correlated with stock price movements, as institutional investors often adjust their valuations based on these estimates, leading to buying or selling actions that affect stock prices [5][6]

Core Viewpoint - Intellicheck Mobilisa, Inc. (IDN) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on an upward trend in earnings estimates [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on changes in a company's earnings picture, tracking EPS estimates from sell-side analysts through a consensus measure [2]. - The recent upgrade reflects a significant increase in earnings estimates, with the Zacks Consensus Estimate for Intellicheck Mobilisa rising by 33.3% over the past three months [9]. Impact of Earnings Estimates on Stock Prices - There is a strong correlation between changes in earnings estimates and near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [5][6]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. Company Performance Outlook - The expected earnings for Intellicheck Mobilisa for the fiscal year ending December 2025 is -$0.03 per share, indicating no year-over-year change [9]. - The upgrade to Zacks Rank 1 positions Intellicheck Mobilisa in the top 5% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [11].

Core Viewpoint - Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardiff Oncology suggest an improvement in the company's underlying business, potentially leading to higher stock prices [5]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Cardiff Oncology is expected to earn -$0.82 per share, reflecting a 13.7% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Cardiff Oncology has increased by 13.1%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Cardiff Oncology to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].